TY  - CONF

T1  - Abstract OT2-01-05: A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy ± radium-223 dichloride in human epidermal growth factor receptor 2–negative, hormone receptor–positive breast cancer patients with bone metastases

JO  - Ongoing Clinical Trials

PY  - 2016/02/15

AU  - Coleman RE

AU  - Huang L

AU  - Petrenciuc O

AU  - Zaccarini P

AU  - Rugo HS

ED  - 

DO  - DOI: 10.1158/1538-7445.sabcs15-ot2-01-05

PB  - American Association for Cancer Research

Y2  - 2025/10/10

ER  -